phase 1b study of dato-dxd in combination with immunotherapy with or without carboplatin in advanced or metastatic non-small cell lung cancer

Conditions: Advanced or Metastatic NSCLC

Summary: this study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (dato-dxd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (nsclc).

the primary objective is to assess the safety and tolerability of dato-dxd in combination with immunotherapy with or without 4 cycles of carboplatin in participants with advanced or metastatic nsclc. two dose levels of dato-dxd will be studied in combination with immunotherapy (durvalumab, azd2936, medi5752, or azd7789) with or without 4 cycles of carboplatin in 15 study cohorts each cohort will start with part 1 (dose escalation or confirmation), where 3 to 9 participants will be assessed for dose-limiting toxicities (dlt) in the first cycle of treatment. if the dlt incidence rate meets the criteria based on the modified toxicity probability interval-2 (mtpi-2), then part 2 (dose expansion) may be opened.

Eligibility criteria:
inclusion criteria: * participant ≥18 years old on the day of signing the icf (local regulatory requirement to consent should be followed). * histologically or cytologically confirmed diagnosis of advanced or metastatic nsclc, without egfr or alk genomic alterations (testing not required for participants with documented squamous histology) and no known genomic alterations in other actionable driver kinases with approved therapies. participants whose tumors harbor kras mutations are eligible for this study. * for cohorts 1 to 4, participants must be treatment-naïve or have received and radiologically progressed after only 1 prior line of systemic chemotherapy, without concomitant immune checkpoint inhibitors for advanced or metastatic nsclc. for cohorts 4a, 5 to 11, and 14, participants must be treatment-naïve for advanced or metastatic nsclc. for cohorts 12 to 13, participants must be cpi acquired resistant after 1 or 2 prior lines of systemic therapy for advanced or metastatic nsclc, of which 1 should have contained an approved anti-pd-1/pd l1. cohort 4a will enroll participants whose tumors have squamous histology only; cohorts 5 part 2a and part 2b as well as cohorts 12 and 13 will enroll participants whose tumors have non-squamous histology only. * willing and able to undergo a mandatory tumor biopsy. a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen may be substituted for the biopsy collected during screening. for cohorts 12 and 13, a tumor sample taken ≤24 months prior to screening is acceptable. * has measurable disease per recist1.1 within 28 days prior to cycle 1 day 1 * eastern co-operative oncology group (ecog) performance status of 0 or 1 at screening * has adequate bone marrow reserve and organ function at baseline within 7 days prior to cycle 1 day 1 * for cohorts 5 to 14 only: documented ihc pd-l1 expression per analytically validated ventana pd-l1 (sp263) ihc assay, 22c3 pharmdx assay, or 28-8 pharmdx assay exclusion criteria: * active or prior documented autoimmune or inflammatory disorders * uncontrolled or significant cardiac disease * history of another primary malignancy with exceptions * active or uncontrolled hepatitis b or c virus or uncontrolled hiv infection * spinal cord compression or clinically active cns metastases * history of (non-infectious) ild/pneumonitis that required steroids * clinically severe pulmonary compromise resulting from intercurrent pulmonary illness * uncontrolled infection requiring iv antibiotics, antivirals, or antifungals * clinically significant corneal disease

Keywords: advanced or metastatic nsclc datopotamab deruxtecan (dato-dxd) ds-1062a durvalumab azd2936 medi5752 azd7789